Subscribe to receive 91outcomes email updates

Monday, September 8, 2014

New Funding Announcement for Gulf War Illness Treatment Researchers

A new funding announcement has been released, as of September 4, 2014, for funding availability for Gulf War Illness treatment medical research.

The following deadlines apply for researchers to apply for funding:


  1. Pre-Application (Preproposal): October 28, 2014
  2. Invitation to Submit an Application: December 2014
  3. Invited Application: January 27, 2015


More information is available from CDMRP:

The press pre-announcement, made earlier, is below.


********


SOURCE:  CDMRP Press Release, Aug. 22, 2014

http://cdmrp.army.mil/pubs/press/2014/14gwirppreann_itea.shtml


ARCHIVED TEXT:

NEWS RELEASE

Released: August 22, 2014

Defense Health Program
Department of Defense Gulf War Illness Research Program
Funding Opportunities for Fiscal Year 2014 (FY14)

The Fiscal Year 2014 (FY14) Defense Appropriations Act provides $20 million (M) to the Department of Defense Gulf War Illness Research Program (GWIRP) to support innovative, high-impact research to improve the health and lives of veterans who have Gulf War Illness (GWI). The GWIRP is administered by the US Army Medical Research and Materiel Command (USAMRMC) through the Office of Congressionally Directed Medical Research Programs (CDMRP).

The GWIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY14 GWIRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in early September 2014. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.
Award MechanismPrincipal Investigator (PI) EligibilityKey Mechanism ElementsFunding
Innovative Treatment Evaluation Award 2Independent investigators at all academic levels (or equivalent).
  • Supports small-scale, early clinical trial evaluations of innovative treatments not previously studied in GWI.
  • Pilot Phase 0, I, and I/II clinical trials are allowed.
  • Provides opportunity to obtain proof of principle data to support future clinical trials.
  • Preliminary data are not required, and if provided, do not necessarily have to come from the GWI research field.
  • Studies with clear potential to move forward to Phase II/III clinical trials are encouraged.
  • Collaboration with industry and/or academic partners is encouraged.
  • Maximum funding of $450,000 for direct costs.
  • Period of performance not to exceed 3 years.
  • Indirect costs may be proposed in accordance with the institution's rate agreement.
All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government's single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. Requests for email notification of the Program Announcements release may be sent tohelp@eBRAP.org. For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website(http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

No comments: